Anna-Marie Hosking
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna-Marie Hosking has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Natasha Atanaskova Mesinkovska
Department of Dermatology, University of California, Irvine, California
3 shared publicationsSebastien de Feraudy
Department of Dermatology, University of California, Irvine, California
3 shared publicationsAshley Elsensohn
Department of Dermatology, University of California, Irvine, California
2 shared publicationsJanellen Smith
Department of Dermatology, University of California, Irvine, California
2 shared publicationsJoy Makdisi
Department of Dermatology, University of California Irvine, Irvine, California
2 shared publicationsMargit Juhasz
Department of Dermatology, University of California, Irvine, California
2 shared publications
Latest Publications
- Open Access
- 15 September 2023
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 7 (5) , 1056-1058
Pink, Painful Nodules: A Case of Cutaneous Metastatic Breast Adenocarcinoma
- 15 September 2023
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 7 (5) , 1056-1058
Open AccessPink, Painful Nodules: A Case of Cutaneous Metastatic Breast Adenocarcinoma
- 7 June 2021
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 47 (9) , 1195-1199
Extraocular Sebaceous Carcinoma Treated With Mohs Micrographic Surgery—A 24-Year Retrospective Review of Tumor Characteristics and Treatment Outcomes
BACKGROUND: Extraocular sebaceous carcinoma (SC) is rare, with distinct features from its ocular counterpart. These neoplasms have been associated with Muir-Torre syndrome (MTS). Associated internal malignancies include gastrointestinal and genitourinary. OBJECTIVE: Assess for local recurrence, metastasis, disease-specific death, and additional malignancies in patients with extraocular SC treated with Mohs micrographic surgery (MMS) at a single referral center. METHODS: Review of patients with extraocular SC treated with MMS between 1995 and 2019. Follow-up was obtained by chart review. RESULTS: Thirty-eight patients with 41 tumors were identified (25, 66% male). During a mean follow-up of 5.9 ± 5 years, one case of metastasis was identified in an incompletely treated case. No recurrence was identified in the remaining 40 tumors. Five of 41 (12%) tumors had aggressive histologic features. Seven of 38 (18%) patients had a diagnosis of MTS or associated risk factors. There was no association between MTS or its risk factors and high-risk tumors. CONCLUSION: There were no incidences of local recurrence, metastasis, or disease-specific death in cases treated completely with MMS. Metastasis and disease-specific death occurred in an incompletely treated case, highlighting the risk associated with aggressive tumors.
- 7 June 2021
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 47 (9) , 1195-1199
Extraocular Sebaceous Carcinoma Treated With Mohs Micrographic Surgery—A 24-Year Retrospective Review of Tumor Characteristics and Treatment Outcomes
BACKGROUND: Extraocular sebaceous carcinoma (SC) is rare, with distinct features from its ocular counterpart. These neoplasms have been associated with Muir-Torre syndrome (MTS). Associated internal malignancies include gastrointestinal and genitourinary. OBJECTIVE: Assess for local recurrence, metastasis, disease-specific death, and additional malignancies in patients with extraocular SC treated with Mohs micrographic surgery (MMS) at a single referral center. METHODS: Review of patients with extraocular SC treated with MMS between 1995 and 2019. Follow-up was obtained by chart review. RESULTS: Thirty-eight patients with 41 tumors were identified (25, 66% male). During a mean follow-up of 5.9 ± 5 years, one case of metastasis was identified in an incompletely treated case. No recurrence was identified in the remaining 40 tumors. Five of 41 (12%) tumors had aggressive histologic features. Seven of 38 (18%) patients had a diagnosis of MTS or associated risk factors. There was no association between MTS or its risk factors and high-risk tumors. CONCLUSION: There were no incidences of local recurrence, metastasis, or disease-specific death in cases treated completely with MMS. Metastasis and disease-specific death occurred in an incompletely treated case, highlighting the risk associated with aggressive tumors.
- 1 November 2020
- Published by Elsevier in Journal of Investigative Dermatology Symposium Proceedings
- Vol. 20 (1) , S50-S54
Monitoring Response to Platelet-Rich Plasma in Patients with Alopecia Areata with Optical Coherence Tomography: A Case Series
- 1 November 2020
- Published by Elsevier in Journal of Investigative Dermatology Symposium Proceedings
- Vol. 20 (1) , S50-S54
Monitoring Response to Platelet-Rich Plasma in Patients with Alopecia Areata with Optical Coherence Tomography: A Case Series
- Open Access
- 17 January 2019
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 51 (3) , 214-222
Hyperspectral imaging in automated digital dermoscopy screening for melanoma
Objectives: Early melanoma detection decreases morbidity and mortality. Early detection classically involves dermoscopy to identify suspicious lesions for which biopsy is indicated. Biopsy and histological examination then diagnose benign nevi, atypical nevi, or cancerous growths. With current methods, a considerable number of unnecessary biopsies are performed as only 11% of all biopsied, suspicious lesions are actually melanomas. Thus, there is a need for more advanced noninvasive diagnostics to guide the decision of whether or not to biopsy. Artificial intelligence can generate screening algorithms that transform a set of imaging biomarkers into a risk score that can be used to classify a lesion as a melanoma or a nevus by comparing the score to a classification threshold. Melanoma imaging biomarkers have been shown to be spectrally dependent in Red, Green, Blue (RGB) color channels, and hyperspectral imaging may further enhance diagnostic power. The purpose of this study was to use the same melanoma imaging biomarkers previously described, but over a wider range of wavelengths to determine if, in combination with machine learning algorithms, this could result in enhanced melanoma detection.Methods: We used the melanoma advanced imaging dermatoscope (mAID) to image pigmented lesions assessed by dermatologists as requiring a biopsy. The mAID is a 21‐wavelength imaging device in the 350–950 nm range. We then generated imaging biomarkers from these hyperspectral dermoscopy images, and, with the help of artificial intelligence algorithms, generated a melanoma Q‐score for each lesion (0 = nevus, 1 = melanoma). The Q‐score was then compared to the histopathologic diagnosis.Results: The overall sensitivity and specificity of hyperspectral dermoscopy in detecting melanoma when evaluated in a set of lesions selected by dermatologists as requiring biopsy was 100% and 36%, respectively.Conclusion: With widespread application, and if validated in larger clinical trials, this non‐invasive methodology could decrease unnecessary biopsies and potentially increase life‐saving early detection events. Lasers Surg. Med. 51:214–222, 2019. © 2019 The Authors.Lasers in Surgery and MedicinePublished by Wiley Periodicals, Inc.
- 17 January 2019
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 51 (3) , 214-222
Open AccessHyperspectral imaging in automated digital dermoscopy screening for melanoma
Objectives: Early melanoma detection decreases morbidity and mortality. Early detection classically involves dermoscopy to identify suspicious lesions for which biopsy is indicated. Biopsy and histological examination then diagnose benign nevi, atypical nevi, or cancerous growths. With current methods, a considerable number of unnecessary biopsies are performed as only 11% of all biopsied, suspicious lesions are actually melanomas. Thus, there is a need for more advanced noninvasive diagnostics to guide the decision of whether or not to biopsy. Artificial intelligence can generate screening algorithms that transform a set of imaging biomarkers into a risk score that can be used to classify a lesion as a melanoma or a nevus by comparing the score to a classification threshold. Melanoma imaging biomarkers have been shown to be spectrally dependent in Red, Green, Blue (RGB) color channels, and hyperspectral imaging may further enhance diagnostic power. The purpose of this study was to use the same melanoma imaging biomarkers previously described, but over a wider range of wavelengths to determine if, in combination with machine learning algorithms, this could result in enhanced melanoma detection.Methods: We used the melanoma advanced imaging dermatoscope (mAID) to image pigmented lesions assessed by dermatologists as requiring a biopsy. The mAID is a 21‐wavelength imaging device in the 350–950 nm range. We then generated imaging biomarkers from these hyperspectral dermoscopy images, and, with the help of artificial intelligence algorithms, generated a melanoma Q‐score for each lesion (0 = nevus, 1 = melanoma). The Q‐score was then compared to the histopathologic diagnosis.Results: The overall sensitivity and specificity of hyperspectral dermoscopy in detecting melanoma when evaluated in a set of lesions selected by dermatologists as requiring biopsy was 100% and 36%, respectively.Conclusion: With widespread application, and if validated in larger clinical trials, this non‐invasive methodology could decrease unnecessary biopsies and potentially increase life‐saving early detection events. Lasers Surg. Med. 51:214–222, 2019. © 2019 The Authors.Lasers in Surgery and MedicinePublished by Wiley Periodicals, Inc.
- Open Access
- 1 January 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (1) , 60-62
A green-brown plaque on the dorsal hand
- 1 January 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (1) , 60-62
Open AccessA green-brown plaque on the dorsal hand
- 2 October 2018
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 45 (12) , 958-961
Keratosis pilaris rubra with mucin deposition
Keratosis pilaris (KP) is a benign cutaneous disorder characterized by folliculocentric hyperkeratotic papules most often occurring on the proximal extremities. Erythema is usually limited to perifollicular skin, but when keratosis pilaris presents on a background of confluent erythema, the term keratosis pilaris rubra (KPR) is used. The histological findings associated with KP have not been well described in the literature. Herein, we present a case of a 14‐year‐old male with a 7‐year history of erythema and follicular‐based papules over his bilateral cheeks, consistent with KPR. Histological examination revealed abundant mucin, keratotic follicular plugging, and periadnexal lymphocytosis. Our novel finding of abundant dermal mucin expands the histopathologic description of KPR.
- 2 October 2018
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 45 (12) , 958-961
Keratosis pilaris rubra with mucin deposition
Keratosis pilaris (KP) is a benign cutaneous disorder characterized by folliculocentric hyperkeratotic papules most often occurring on the proximal extremities. Erythema is usually limited to perifollicular skin, but when keratosis pilaris presents on a background of confluent erythema, the term keratosis pilaris rubra (KPR) is used. The histological findings associated with KP have not been well described in the literature. Herein, we present a case of a 14‐year‐old male with a 7‐year history of erythema and follicular‐based papules over his bilateral cheeks, consistent with KPR. Histological examination revealed abundant mucin, keratotic follicular plugging, and periadnexal lymphocytosis. Our novel finding of abundant dermal mucin expands the histopathologic description of KPR.
- 6 September 2018
- Published by Wiley in Pediatric Dermatology
- Vol. 35 (6) , E348-E352
Diffuse cutaneous mastocytosis: Case report and literature review
A 6‐month‐old boy was referred to our burn unit with a recurrent bullous dermatitis, fever, and emesis, originally diagnosed as staphylococcal scalded skin syndrome (SSSS) at an outside hospital. Infectious workup was negative and shave biopsy revealed a dense, diffuse dermal infiltrate of mast cells, consistent with diffuse cutaneous bullous mastocytosis—a rare variant of cutaneous mastocytosis. Treatment included a prolonged course of corticosteroids and antihistamines. Recognition of this rare form of mastocytosis is important, as it can be easily mistaken for other pediatric bullous diseases and is associated with life‐threatening complications including vasodilation, anaphylactic shock, gastrointestinal bleeding, and death.
- 6 September 2018
- Published by Wiley in Pediatric Dermatology
- Vol. 35 (6) , E348-E352
Diffuse cutaneous mastocytosis: Case report and literature review
A 6‐month‐old boy was referred to our burn unit with a recurrent bullous dermatitis, fever, and emesis, originally diagnosed as staphylococcal scalded skin syndrome (SSSS) at an outside hospital. Infectious workup was negative and shave biopsy revealed a dense, diffuse dermal infiltrate of mast cells, consistent with diffuse cutaneous bullous mastocytosis—a rare variant of cutaneous mastocytosis. Treatment included a prolonged course of corticosteroids and antihistamines. Recognition of this rare form of mastocytosis is important, as it can be easily mistaken for other pediatric bullous diseases and is associated with life‐threatening complications including vasodilation, anaphylactic shock, gastrointestinal bleeding, and death.
- 1 September 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 79 (3) , 535-544
Topical Janus kinase inhibitors: A review of applications in dermatology
- 1 September 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 79 (3) , 535-544
Topical Janus kinase inhibitors: A review of applications in dermatology
- 21 August 2018
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 5 (2) , 72-89
Complementary and Alternative Treatments for Alopecia: A Comprehensive Review
The treatment of alopecia is limited by a lack of therapies that induce and sustain disease remission. Given the negative psychosocial impact of hair loss, patients that do not see significant hair restoration with conventional therapies often turn to complementary and alternative medicine (CAM). Although there are a variety of CAM treatment options on the market for alopecia, only a few are backed by multiple randomized controlled trials. Further, these modalities are not regulated by the Food and Drug Administration and there is a lack of standardization of bioactive in gredients in over-the-counter vitamins, herbs, and supplements. In this article, we provide a comprehensive review of the efficacy, safety, and tolerability of CAM, including natural products and mind and body practices, in the treatment of hair loss. Overall, there is a need for additional studies investigating CAM for alopecia with more robust clinical design and standardized, quantitative outcomes.
- 21 August 2018
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 5 (2) , 72-89
Complementary and Alternative Treatments for Alopecia: A Comprehensive Review
The treatment of alopecia is limited by a lack of therapies that induce and sustain disease remission. Given the negative psychosocial impact of hair loss, patients that do not see significant hair restoration with conventional therapies often turn to complementary and alternative medicine (CAM). Although there are a variety of CAM treatment options on the market for alopecia, only a few are backed by multiple randomized controlled trials. Further, these modalities are not regulated by the Food and Drug Administration and there is a lack of standardization of bioactive in gredients in over-the-counter vitamins, herbs, and supplements. In this article, we provide a comprehensive review of the efficacy, safety, and tolerability of CAM, including natural products and mind and body practices, in the treatment of hair loss. Overall, there is a need for additional studies investigating CAM for alopecia with more robust clinical design and standardized, quantitative outcomes.
- Open Access
- 1 January 2018
- Published by Medknow in International Journal of Trichology
- Vol. 10 (6) , 286-288
Suspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis
Systemic administration of Janus kinase inhibitors (JAKis) is associated with adverse events, including serious infections, malignancy, and herpes zoster (HZ). Herein, we report a case of a 17-year-old male with alopecia universalis who developed suspected HZ-associated encephalitis (HZAE) during treatment with oral tofacitinib. Oral tofacitinib was immediately discontinued, and the patient was started on antiviral treatment. We present this case to highlight a serious complication that can arise with oral JAKi therapy. Physicians should have a high index of clinical suspicion for HZAE in any patient presenting with a vesicular rash and concomitant neurologic impairments while systemically immunosuppressed.
- 1 January 2018
- Published by Medknow in International Journal of Trichology
- Vol. 10 (6) , 286-288
Open AccessSuspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis
Systemic administration of Janus kinase inhibitors (JAKis) is associated with adverse events, including serious infections, malignancy, and herpes zoster (HZ). Herein, we report a case of a 17-year-old male with alopecia universalis who developed suspected HZ-associated encephalitis (HZAE) during treatment with oral tofacitinib. Oral tofacitinib was immediately discontinued, and the patient was started on antiviral treatment. We present this case to highlight a serious complication that can arise with oral JAKi therapy. Physicians should have a high index of clinical suspicion for HZAE in any patient presenting with a vesicular rash and concomitant neurologic impairments while systemically immunosuppressed.